Johnson & Johnson, the manufacturer of various pharmaceuticals, can't seem to get things right this year. The company recently announced its fifth recall of 2011, pulling nearly 2.5 million packages of Tylenol Cold Multi-Symptom Nighttime Rapid Release Gelcaps from retailers' shelves.
The recall comes after regular monitoring procedures found that some of the samples contained levels of chlorpheniramine ammonio acetate higher than the product labels designated. However, McNeil Consumer Healthcare Division, a part of the Johnson & Johnson family, said consumers could continue to safely use the product, The Philadelphia Inquirer reports.
Consumers have not let the recalls go unpunished, though. According to a blog post by Katherine Hobson in The Wall Street Journal, in 2010, product recalls cost the company approximately $900 million in sales and resulted in a 12 percent drop in profit for the fourth quarter.
In fact, since the beginning of the year, Johnson & Johnson has been forced to remove packages of Sudafad, Benadryl, Sinutab, Tylenol and Topomax from stores' shelves as a result of manufacturing and labeling problems, Hobson notes.